These findings suggest that, although plasma EV-EAAT2 levels are significantly increased in all clinical MS forms respect to healthy controls, the highest EV-EAAT2 levels are observed in relapsing RRMS patients. Here, SLC1A2 is linked to myeloid sarcoma.